Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.27, Iss.1, 2009-01, pp. : 69-80
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Olanzapine and risperidone on a par in schizophrenia
Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. :